揭开风险:使用FAERS的现实数据对药物诱导的口腔进行了全面分析
Xuefeng Wang1, Yingxue Huang, Yanbo Zhang
1Department of Stomatology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China.
Medicine
|March 6, 2026
概括
这项研究确定了426种与口腔相关的药物,其中因弗力西马布,甲铁和埃弗罗利莫斯是主要的罪祸首. 早期识别和患者教育对于预防这些药物诱导的口腔病变至关重要.
科学领域:
- 药物监督 药物监督 药物监督
- 口腔医学是指口腔医学.
- 临床药理学 临床药理学
背景情况:
- 药物诱导的口腔是一种日益严重的临床问题,流行病学尚不清楚.
- 现实世界的数据分析对于理解与药物相关的不良事件至关重要.
研究的目的:
- 调查各种药物与药物诱导的口腔之间的关联.
- 为了确定风险因素,并比较不同类别的药物发病时间.
主要方法:
- 对美国FDA不良事件报告系统 (FAERS) 数据的分析 (2015年第三季度-2024年第四季度).
- 利用不成比例分析和贝叶斯算法来识别相关药物.
- 使用后勤回归来确定独立的风险因素.
主要成果:
- 在FAERS数据库中,有426种药物与口腔有关.
- 鉴定出因弗利西玛布,甲铁酸盐,埃弗罗利斯,塞库金纳布和帕尔博西克利布是具有显著风险的前五种药物.
- 年龄,性别,并发症和特定药物是独立的风险因素;大多数药物都显示出早期发病.
结论:
- 识别特定的药物风险对于以预防为重点的管理策略至关重要.
- 医疗保健专业人员必须向患者宣传口腔的潜在药物风险.
- 提高意识和监测可以减少与药物相关的口腔粘膜病变.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.8K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.8K
Peptic Ulcer Disease IV: Management
598
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
598
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.4K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.4K
Pharmacovigilance
1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
730
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
730
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
1.1K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.1K

